US
IN
AU
JP
BM
CA
In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesity In addition to weight loss, retatrutide reduced knee osteoarthritis pain by up to 4.3 points (73.
1%) and moderate-to-severe obstructive sleep apnea severity by up to 36.1 events per hour (60.6%) In TRANSCEND-T2D-1, participants on retatrutide achieved A1C reductions of up to 2.0% and weight loss of up to 36.6 lbs (16.
8%) at 40 weeks, with up to 46% achieving a normal A1C INDIANAPOLIS, June 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced additional positive results from pivotal Phase 3 trials of retatrutide, an investigational, first-in-class GIP, GLP-1,...
Read more
